A Phase 2 interventional study of Fisetin and Placebo in Common Variable Immunodeficiency and Interstitial Lung Disease Due to Systemic Disease, sponsored by Avni Joshi. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by Avni Joshi · Phase 2, Interventional, and Treatment
The purpose of this study is to determine if the supplement, Fisetin, can be used as a treatment option for common variable immunodeficiency (CVID) by comparing its efficacy to placebo.
Exclusion Criteria:
WCBP who are unwilling to abstain from sex or use an adequate method of contraception from the time of the first IP administration through 48 hours after the last IP administration.
Subjects will receive the supplement, Fisetin, for 2 cycles of 2 consecutive days (first on days 0 \& 1 and then repeated on days 28 \& 29)
Drug: Fisetin
Subjects will receive placebo for 2 cycles of 2 consecutive days (first on days 0 \& 1 and then repeated on days 28 \& 29)
Drug: Placebo
20 mg per kilogram (kg) of body weight supplied in 100 mg capsules and administered orally on days 0, 1, 28, and 29
Looks exactly like the study drug, but it contains no active ingredient. Administered orally on days 0, 1, 28 and 29
Change in immunophenotyping of peripheral T lymphocytes
Measured by percentage of activated CD4+25+ T cells
Time frame: Baseline, 6 months
Change in Forced Vital Capacity (FVC)
Measured by spirometry to determine the maximal amount of air that can be forcibly exhaled from the lungs after a full inhale, reported as liters (L)
Time frame: Baseline, 6 months
Change in radiologic imaging in subjects
Number of subjects to have a 10% improvement with the CT scoring system. Radiologist will score the CT scans at each time point and changes in score at each time point will be noted.
Time frame: Baseline, 3 months, 6 months
Use of MRI imaging for assessment of GLILD
Number of MRI images that were used to assess for GLILD compared to High-resolution Computed Tomography (HRCT) use
Time frame: 6 months
Infectious complications
Number of subjects to experience infectious complications
Time frame: 6 months
Adverse Events
Number of adverse events reported
Time frame: 6 months
Change in quality of life
Measured using the RAND 36-Short Form Survey Instrument (SF-36). The SF-36 Health Survey is a 36-item, participant-reported survey that measures patient health and disability. Possible scores range from 0 to 100, with 0 indicating maximum disability, and 100 indicating no disability
Time frame: Baseline, 6 months
Change in 6 minute walk test
Number of subjects to have a 10% improvement in 6 minute walk test. The 6 minute walk test measures the distance a person is able to walk in 6 minutes.
Time frame: Baseline, 6 months
Plan to share: No
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Common Variable Immunodeficiency→